Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer

NCT05253066 | Unknown Phase 2

• 1 other identifier: MUKDEN5
• Study Type: interventional
• Target: 130
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is an open, multicenter, randomized controlled clinical study aimed to explore the efficacy and safety of chidamide combined with exemestane (+/- goserelin) versus chemotherapy in the neoadjuvant treatment of stage II-III HR +/HER2- breast cancer patients with poor response to previous chemotherapy.

Conditions

Breast Neoplasms

Outcome Measures

Primary Outcomes (1)

• ORR

  Up to approximately 48 months

Secondary Outcomes (8)

• pCR：Upon completion of neoadjuvant therapy and surgery, there was no residual invasive carcinoma present in the pathologic assessment of the resected breast cancer samples stained with hematoxylin and eosin and all ipsilateral lymph node samples.

  Up to approximately 48 months

• Residual tumor burden (RCB) classification

  Up to approximately 48 months

• Total breast pathological complete remission rate (bpCR)

  Up to approximately 48 months

• PEPI classification

  Up to approximately 48 months

• Breast-conserving rate

  Up to approximately 48 months

Study Arms (2)

Chidamide group

EXPERIMENTAL

Chidamide combined with exemestane (+/- goserelin)

Drug: Chidamide combined with exemestane (+/- goserelin)

chemotherapy group

ACTIVE COMPARATOR

Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician)

Drug: Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician)

Interventions

Chidamide combined with exemestane (+/- goserelin) DRUG

Chidamide combined with exemestane (+/- goserelin)

Chidamide group

Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician) DRUG

Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician)

chemotherapy group

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• female patients aged greater than or equal to 18 years and less than or equal to 75 years, meet one of the following:
• previous oophorectomy, or age ≥ 60 years;
• age \< 60 years, natural postmenopausal status (defined as at least 12 consecutive months of spontaneous cessation of regular menstruation, and no other pathological or physiological causes), E2 and FSH in postmenopausal levels;
• premenopausal or perimenopausal female patients, must be willing to receive LHRH agonist therapy during the study;
• all patients were confirmed by histopathology as estrogen receptor (ER) positive (\> 10%), HER2 receptor negative.Follow the 2018 version of ASCO-CAP HER2-negative interpretation guideline criteria;
• tumor stage II-III meeting the AJCC 8th version criteria, patients who have previously received 2 cycles of TE regimen chemotherapy, with disease evaluation of SD or PD;
• KPS score ≥ 70 points;
• organ function level must meet the following requirements:
• bone marrow function ANC ≥ 1.5 × 109/L (14 without growth factors); PLT ≥ 100 × 109/L (7 without corrective treatment); Hb ≥ 100 g/L (7) without corrective treatment;
• liver and kidney function TBIL ≤ 1.5 × ULN; ALT and AST ≤ 3 × ULN; BUN and Cr ≤ 1.5 × ULN and creatinine clearance ≥ 50 mL/min (Cockcroft-Gault formula);
• able to undergo needle biopsy;
• voluntarily join this study, sign informed consent, have good compliance and are willing to cooperate with follow-up

You may not qualify if:

• received any form of anti-tumor therapy (chemotherapy, radiotherapy, molecular targeted therapy, endocrine therapy, etc.);
• received any other anti-tumor therapy at the same time;
• breast cancer, inflammatory breast cancer or occult breast cancer;
• stage IV breast cancer;
• breast cancer without histopathological diagnosis;

Sponsors & Collaborators

• Shengjing Hospital: lead

MeSH Terms

Conditions

Breast Neoplasms

Interventions

exemestane; Goserelin; Drug Therapy; Docetaxel; Epirubicin

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Gonadotropin-Releasing Hormone; Pituitary Hormone-Releasing Hormones; Hypothalamic Hormones; Peptide Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Neuropeptides; Peptides; Amino Acids, Peptides, and Proteins; Oligopeptides; Nerve Tissue Proteins; Proteins; Therapeutics; Taxoids; Cyclodecanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Diterpenes; Terpenes; Doxorubicin; Daunorubicin; Anthracyclines; Naphthacenes; Polycyclic Aromatic Hydrocarbons; Hydrocarbons, Aromatic; Polycyclic Compounds; Aminoglycosides; Glycosides; Carbohydrates

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director

Study Record Dates

• First Submitted: January 13, 2022
• First Posted: February 23, 2022
• Study Start: February 25, 2022
• Primary Completion: July 31, 2022
• Study Completion: January 31, 2025
• Last Updated: February 23, 2022

Record last verified: 2022-02